CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML PatientsBusiness Wire • 3 months agoCERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ('CERo') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic...